scispace - formally typeset
Search or ask a question
Institution

Central Drug Research Institute

FacilityLucknow, Uttar Pradesh, India
About: Central Drug Research Institute is a facility organization based out in Lucknow, Uttar Pradesh, India. It is known for research contribution in the topics: Catalysis & Leishmania donovani. The organization has 4357 authors who have published 7257 publications receiving 143871 citations. The organization is also known as: Central Drug Research Institute, Lucknow & CDRI.


Papers
More filters
Journal ArticleDOI
TL;DR: An efficient and convenient synthesis of 2-amino-6-aryl-4-methylsulfanylnicotinonitriles, as well as base-catalyzed ring transformation of 6- Daryl-3-cyano- 4-methylSulfanyl/substituted-AMino-2H-pyran-2-ones with cyanamide and ammonium carbonate separately.
Abstract: An efficient and convenient synthesis of 2-amino-6-aryl-4-methylsulfanylnicotinonitriles (2), 2-amino-6-aryl-4-substituted-aminonicotinonitriles (4), and 2-amino-6-aryl-4-substituted-aminopyridines (6) has been delineated and illustrated through base-catalyzed ring transformation of 6-aryl-3-cyano-4-methylsulfanyl/substituted-amino-2H-pyran-2-ones (1, 3, and 5) with cyanamide and ammonium carbonate separately.

68 citations

Journal ArticleDOI
TL;DR: SBME produced significant improvement on mental control, logical memory and paired associated learning during the 12-week drug therapy and is efficacious in subjects with age-associated memory impairment.
Abstract: Background: Brahmi (Bacopa monniera) is a traditional Indian medicinal plant which causes multiple effects on the central nervous system. The standardized extract of this plant has shown enhanced behavioural learning in preclinical studies and enhanced information processing in healthy volunteers. Aim: To study the efficacy of standardized Bacopa monniera extract (SBME) in subjects with age-associated memory impairment (AAMI) without any evidence of dementia or psychiatric disorder. Methods: A double-blind, placebo-controlled randomized study design was employed. The subjects received either 125 mg of SBME or placebo twice a day for a period of 12 weeks followed by a placebo period of another 4 weeks (total duration of the trial 16 weeks). Each subject was evaluated for cognition on a battery of tests comprising mental control, logical memory, digit forward, digit backward, visual reproduction and paired associate learning. Results: SBME produced significant improvement on mental control, logical memory and paired associated learning during the 12-week drug therapy. Conclusion: SBME is efficacious in subjects with age-associated memory impairment.

68 citations

Journal ArticleDOI
TL;DR: Two new iridoids 6-O-[2,3-dimethoxy]-trans-cinnamoyl catalpol and 6- O-meta-methoxy-benzoylCatalpol are reported from Cissus quadrangularis Linn, the first reported occurrence of iridoid picroside 1 and the compounds 3 and 7 are first reported from this plant.

68 citations

Journal ArticleDOI
TL;DR: In this article, an efficient non-ionic surfactant catalyzed multicomponent synthesis of novel benzylamino coumarin derivatives has been developed from secondary amines, aromatic aldehyde, and 4-hydroxymethylcoumarin via Mannich type reaction in aqueous media.

68 citations

Journal ArticleDOI
TL;DR: How NMR and spin‐label electron paramagnetic resonance spectroscopy and selective mutagenesis can be combined to provide a structural basis towards understanding the mechanism of influenza hemagglutinin‐mediated membrane fusion is summarized.

68 citations


Authors

Showing all 4385 results

NameH-indexPapersCitations
Sanjay Kumar120205282620
John A. Katzenellenbogen9569136132
Brajesh K. Singh8340124101
Gaurav Sharma82124431482
Sudhir Kumar82524216349
Pramod K. Srivastava7939027330
Mohan K. Raizada7547321452
Syed F. Ali7144618669
Ravi Shankar6667219326
Ramesh Chandra6662016293
Manoj Kumar6540816838
Manish Kumar61142521762
Anil Kumar Saxena5831010107
Sanjay Krishna5662413731
Naibedya Chattopadhyay562429795
Network Information
Related Institutions (5)
Merck & Co.
48K papers, 1.9M citations

93% related

GlaxoSmithKline
21.1K papers, 1.1M citations

92% related

Bristol-Myers Squibb
21K papers, 932.5K citations

92% related

Novartis
50.5K papers, 1.9M citations

91% related

Pfizer
37.4K papers, 1.6M citations

91% related

Performance
Metrics
No. of papers from the Institution in previous years
YearPapers
20233
202256
2021307
2020232
2019246
2018289